Zacks Investment Research downgraded shares of Intec Pharma (NASDAQ:NTEC) from a hold rating to a sell rating in a report released on Friday, March 16th.
According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
Several other equities research analysts have also weighed in on the company. Oppenheimer set a $15.00 price objective on Intec Pharma and gave the company a buy rating in a research note on Thursday, November 16th. Ladenburg Thalmann Financial Services initiated coverage on Intec Pharma in a research note on Wednesday, February 28th. They issued a buy rating on the stock. Maxim Group set a $8.00 price target on Intec Pharma and gave the stock a buy rating in a research report on Friday, November 17th. ValuEngine lowered Intec Pharma from a hold rating to a sell rating in a research report on Thursday, November 16th. Finally, HC Wainwright restated a buy rating and set a $16.00 price target on shares of Intec Pharma in a research report on Monday, March 12th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. Intec Pharma currently has a consensus rating of Buy and a consensus price target of $12.67.
Shares of NASDAQ NTEC traded down $0.20 during trading hours on Friday, hitting $6.30. 48,289 shares of the company’s stock were exchanged, compared to its average volume of 58,068. The stock has a market capitalization of $169.49, a PE ratio of -3.82 and a beta of 1.26. Intec Pharma has a 1-year low of $4.80 and a 1-year high of $9.80.
Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings results on Friday, March 9th. The biotechnology company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). sell-side analysts predict that Intec Pharma will post -1.15 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of NTEC. Caxton Corp acquired a new stake in Intec Pharma during the 3rd quarter worth $681,000. Sectoral Asset Management Inc bought a new position in Intec Pharma during the 3rd quarter worth about $3,177,000. Pura Vida Investments LLC bought a new position in Intec Pharma during the 3rd quarter worth about $895,000. Renaissance Technologies LLC increased its holdings in Intec Pharma by 66.0% during the 4th quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock worth $688,000 after purchasing an additional 53,100 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in Intec Pharma by 59.2% during the 4th quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 42,867 shares in the last quarter. 41.39% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Intec Pharma (NTEC) Downgraded to “Sell” at Zacks Investment Research” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/intec-pharma-ntec-downgraded-to-sell-at-zacks-investment-research.html.
About Intec Pharma
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Get a free copy of the Zacks research report on Intec Pharma (NTEC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.